An increasing number of studies have suggested that PARP inhibition, using predominantly either veliparib or olaparib, leads to the accumulation of DSBs and enhanced radiosensitivity of both HPV-positive and HPV-negative HNSCC cells [reviewed in 18)]. Here, PARP1 is linked to head and neck squamous cell carcinoma.